SCHEMBL2022299

SCHEMBL2022299

Cc1cccc(C)c1-c1nnc(N(C)C2CCCc3ccccc32)c2ccccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.40
XBP1 P17861 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.38
TAS1R3 Q7RTX0 1/20 0.37
TAS1R1 Q7RTX1 1/20 0.37
TAS1R2 Q8TE23 1/20 0.37
IDO1 P14902 2/20 0.34
CHRNB2 P17787 1/20 0.34
CHRNA4 P43681 1/20 0.34
USP2 O75604 1/20 0.34
PER2 O15055 1/20 0.34
CRY1 Q16526 1/20 0.34
CRY2 Q49AN0 1/20 0.34
MEN1 O00255 1/20 0.34
P4HB P07237 1/20 0.34
KMT2A Q03164 1/20 0.34
CD38 P28907 2/20 0.33
TRPM8 Q7Z2W7 1/20 0.33
MAOA P21397 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12574543 1.00 ALDH1A1 (0.40) ALDH1A1XBP1HTTRAB9ATAS1R3
SCHEMBL2020824 0.88 ALDH1A1 (0.35) ALDH1A1XBP1HTTRAB9ACHRNB2
SCHEMBL2024607 0.84 MAOA (0.38) ALDH1A1XBP1HTTPER2CRY1
SCHEMBL2017025 0.81 RAB9A (0.39) ALDH1A1XBP1HTTRAB9ATAS1R3
SCHEMBL12574544 0.79 MAP3K14 (0.35)
SCHEMBL2019380 0.79 RAB9A (0.36) ALDH1A1XBP1HTTRAB9ATAS1R3
SCHEMBL2015639 0.78 ALDH1A1 (0.38) ALDH1A1XBP1HTTRAB9ATAS1R3
SCHEMBL12750351 0.74 MEN1 (0.42) ALDH1A1XBP1HTTRAB9ATAS1R3
SCHEMBL2019595 0.74 MAOA (0.35) RAB9APER2CRY1CRY2MAOA
SCHEMBL2019614 0.74 IDO1 (0.46) TAS1R3TAS1R1TAS1R2IDO1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338591-B2 3-aryl-5,6-disubstituted pyridazines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-12-25 US claimed
US-8338591-B2 3-aryl-5,6-disubstituted pyridazines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-12-25 US disclosed
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines NEUROGEN CORPORATION (US) 2011-06-30 US disclosed
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines NEUROGEN CORPORATION (US) 2011-06-30 US disclosed
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines NEUROGEN CORPORATION (US) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160187-A1 3-aryl-5,6-disubstituted pyridazines MMP25, MMP9, MMP3 ALDH1A1 403/4885XBP1 3930/4885HTT 3469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.